IGM Biosciences Inc. (IGMS) Misses Q2 EPS by 75c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Morgan Stanley Reiterates Overweight Rating on IGM Biosciences (IGMS)
August 14, 2024 12:04 PM EDTMorgan Stanley analyst Michael Ulz reiterated an Overweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "Reported 2Q24 highlighted progress across the early stage pipeline as Ph1b dose escalation continues for imvotamab in RA and... More
